TY - JOUR
T1 - Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache
T2 - A six-month follow-up of the COMOESTAS Project
AU - Bottiroli, Sara
AU - Allena, Marta
AU - Sances, Grazia
AU - De Icco, Roberto
AU - Avenali, Micol
AU - Fadic, Ricardo
AU - Katsarava, Zaza
AU - Lainez, Miguel Ja
AU - Goicochea, Maria Teresa
AU - Bendtsen, Lars
AU - Jensen, Rigmor Højland
AU - Nappi, Giuseppe
AU - Tassorelli, Cristina
AU - COMOESTAS Consortium
PY - 2019
Y1 - 2019
N2 - AIM: To identify factors that may be predictors of the outcome of a detoxification treatment in medication-overuse headache.METHODS: Consecutive patients entering a detoxification program in six centres in Europe and Latin America were evaluated and followed up for 6 months. We evaluated anxious and depressive symptomatology (though patients with severe psychiatric comorbidity were excluded), quality of life, headache-related disability, headache characteristics, and prophylaxis upon discharge.RESULTS: Of the 492 patients who completed the six-month follow up, 407 ceased overuse following the detoxification (non overusers), another 23 ceased overuse following detoxification but relapsed during the follow-up. In the 407 non-overusers, headache acquired an episodic pattern in 287 subjects (responders). At the multivariate analyses, lower depression scores (odds ratio = 0.891; p = 0.001) predicted ceasing overuse. The primary headache diagnosis - migraine with respect to tension-type headache (odds ratio = 0.224; p = 0.001) or migraine plus tension-type headache (odds ratio = 0.467; p = 0.002) - and the preventive treatment with flunarizine (compared to no such treatment) (odds ratio = 0.891; p = 0.001) predicted being a responder. A longer duration of chronic headache (odds ratio = 1.053; p = 0.032) predicted relapse into overuse. Quality of life and disability were not associated with any of the outcomes.CONCLUSIONS: Though exploratory in nature, these findings point to specific factors that are associated with a positive outcome of medication-overuse headache management, while identifying others that may be associated with a negative outcome. Evaluation of the presence/absence of these factors may help to optimize the management of this challenging groups of chronic headache sufferers.
AB - AIM: To identify factors that may be predictors of the outcome of a detoxification treatment in medication-overuse headache.METHODS: Consecutive patients entering a detoxification program in six centres in Europe and Latin America were evaluated and followed up for 6 months. We evaluated anxious and depressive symptomatology (though patients with severe psychiatric comorbidity were excluded), quality of life, headache-related disability, headache characteristics, and prophylaxis upon discharge.RESULTS: Of the 492 patients who completed the six-month follow up, 407 ceased overuse following the detoxification (non overusers), another 23 ceased overuse following detoxification but relapsed during the follow-up. In the 407 non-overusers, headache acquired an episodic pattern in 287 subjects (responders). At the multivariate analyses, lower depression scores (odds ratio = 0.891; p = 0.001) predicted ceasing overuse. The primary headache diagnosis - migraine with respect to tension-type headache (odds ratio = 0.224; p = 0.001) or migraine plus tension-type headache (odds ratio = 0.467; p = 0.002) - and the preventive treatment with flunarizine (compared to no such treatment) (odds ratio = 0.891; p = 0.001) predicted being a responder. A longer duration of chronic headache (odds ratio = 1.053; p = 0.032) predicted relapse into overuse. Quality of life and disability were not associated with any of the outcomes.CONCLUSIONS: Though exploratory in nature, these findings point to specific factors that are associated with a positive outcome of medication-overuse headache management, while identifying others that may be associated with a negative outcome. Evaluation of the presence/absence of these factors may help to optimize the management of this challenging groups of chronic headache sufferers.
U2 - 10.1177/0333102418783317
DO - 10.1177/0333102418783317
M3 - Journal article
C2 - 29945464
SN - 0333-1024
VL - 39
SP - 135
EP - 147
JO - Cephalalgia : an international journal of headache
JF - Cephalalgia : an international journal of headache
IS - 1
ER -